Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CeriBell, Inc. (Nasdaq: CBLL) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a medical technology company focused on point-of-care electroencephalography (EEG) for serious neurological conditions, CeriBell uses its filings to report financial performance, material agreements, intellectual property actions, and key product milestones related to the Ceribell System.
Investors can review periodic reports and current reports on Form 8-K that describe quarterly financial results, including separate disclosure of product revenue and subscription revenue, as well as updates on cash, marketable securities, and operating expenses. Filings also cover material definitive agreements, such as the Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University for patent rights related to portable brain wave devices, and the Corporate Supply Agreement with Shenzhen Everwin Precision Technology Co., Ltd. and affiliates for EEG headband supply and related licenses.
Other 8-K filings document regulatory and legal developments, including announcements of FDA 510(k) clearance for the Clarity® algorithm in neonatal seizure detection, clearance for the company’s delirium monitoring solution, and the FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor. Filings also describe patent infringement complaints filed against Natus Medical Incorporated and related subsidiaries, as well as lease amendments for office space in Sunnyvale, California and governance changes such as the election of new directors.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand financial trends, material contracts, regulatory events, and intellectual property issues affecting CBLL. Users can also track insider-related disclosures when available through forms such as Form 4, and refer to annual reports on Form 10-K and quarterly reports on Form 10-Q for deeper insight into CeriBell’s business, risk factors, and operations.
Ceribell, Inc. reported that, effective September 17, 2025, its Board of Directors elected Erica Rogers to serve as a director until the next annual meeting of stockholders and until a successor is duly elected and qualified, or her earlier resignation or removal.
She has also been appointed to the Board’s Compensation Committee. As a non-employee director, Ms. Rogers will receive annual cash compensation and restricted stock units under Ceribell’s Non-Employee Director Compensation Program, and the company will enter into its standard-form indemnification agreement with her. The company states there is no arrangement or understanding with any other person regarding her election and that she is not involved in related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Ceribell director Erica J. Rogers filed an initial Form 3 reporting her relationship to Ceribell, Inc. (CBLL) with an event date of 09/17/2025. The filing states that no securities are beneficially owned by the reporting person. The form was signed by an attorney-in-fact, Louisa Daniels, on 09/19/2025, and includes Exhibit 24 (Power of Attorney).
Ceribell, Inc. (CBLL) director Erica J. Rogers was granted 25,216 restricted stock units (RSUs) on 09/17/2025. The RSUs are reported at a $0 transaction price, and following the grant she is shown as beneficially owning 25,216 shares on a direct basis. The Form 4 was signed on behalf of Ms. Rogers by attorney-in-fact Louisa Daniels on 09/19/2025. The filing identifies Ms. Rogers as a director and indicates this is a single-person Form 4 filing for the issuer Ceribell, Inc., ticker CBLL. No derivative securities or other transactions are reported in this filing.
Ceribell, Inc. (CBLL) insider amendment corrects earlier Form 4 by reporting option exercises the CEO and director executed on April 22 and April 23, 2025. The reporting person, President and CEO Xingjuan Chao, exercised options at $2.24 per share: 300 options on 04/22/2025 and 15,628 options on 04/23/2025. Those exercises increased reported beneficial ownership to 752,451 shares after 04/22 and to 768,079 shares after 04/23. The filing states the transactions were effected under a Rule 10b5-1 trading plan and that the omitted exercises caused understatement in the original filing’s ownership totals. The amendment clarifies that the stock options are fully vested and exercisable.
Ceribell, Inc. (CBLL) reporting person Jane (Xingjuan) Chao filed an amended Form 4/A to correct omitted option exercises that occurred on April 17, 2025 and April 21, 2025. The amendment shows the exercise of 5,700 options on 04/17/2025 and 3,372 options on 04/21/2025 at a conversion/exercise price of $2.24 per share. The filings report resulting beneficial ownership totals of 757,851 and 761,223 common shares following those transactions. The Form states the option exercises were effected under a Rule 10b5-1 trading plan and that the options are fully vested and exercisable. The amendment was filed to correct understated ownership amounts in the original Form 4, which accurately reported the number of shares sold but omitted the immediate pre-sale exercises.
Raymond Woo, Chief Technology Officer of Ceribell, Inc. (CBLL), reported option exercises and a sale executed under a Rule 10b5-1 trading plan on 09/04/2025. He exercised a stock option with a $2.24 exercise price for 1,472 shares, and two options with $4.70 exercise prices for 3,025 and 6,615 shares, respectively. Following those exercises his reported common stock beneficial ownership increased in interim steps to 178,816 shares and then, after a sale, decreased to 167,704 shares. He sold 11,112 shares at a weighted-average price of $12.11 (individual sale prices ranged $12.00–$12.34). The Form 4 states the option exercises and sales were effected pursuant to a Rule 10b5-1 plan and notes vesting schedules and exercisability for the reported options.
Rebecca B. Robertson, a director of Ceribell, Inc. (CBLL), reported a sale of 827 shares of the issuer's common stock on 09/03/2025 at a reported price of $11.36 per share under a Rule 10b5-1 trading plan. After the reported transaction Ms. Robertson beneficially owned 9,215 shares, held directly. The Form 4 was filed as a one-person filing and signed by an attorney-in-fact on behalf of the reporting person.
The filing states the sale was effected pursuant to a 10b5-1 plan, indicating the transaction was prearranged. No derivative transactions, option exercises, or additional securities classes are reported in this Form 4.
CeriBell, Inc. filed a Form 144 notifying the proposed sale of 11,112 common shares via Fidelity Brokerage Services on or about 09/04/2025 on the NASDAQ. The filing reports an aggregate market value of $134,609.87 against 36,663,968 shares outstanding, indicating the shares represent approximately 0.03% of the outstanding common stock. The shares arise from option exercises: 1,472 shares from an option granted 07/07/2021 and 9,640 shares from an option granted 02/16/2023, with cash payment recorded on 09/04/2025. The filer reports no sales in the prior three months. The form contains standard representations about material nonpublic information and signature attestation.
Ceribell, Inc. insider Raymond Woo, the company's Chief Technology Officer, exercised options under a Rule 10b5-1 plan on 09/02/2025. He acquired 20,000 shares of Common Stock by exercising stock options at a $2.24 exercise price. Following the transaction, the reporting person beneficially owns 167,704 shares of common stock and directly holds 20,000 underlying shares from the exercised option. The option granted is fully vested and exercisable and has an expiration date of 06/10/2029. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
CeriBell, Inc. (CBLL) submitted a Form 144 notice showing a proposed sale of 827 common shares acquired through restricted stock vesting on 09/01/2025. The filing lists an approximate sale date of 09/03/2025 through Fidelity Brokerage Services, with an aggregate market value of $9,394.72 based on the filing. The issuer has 36,663,968 shares outstanding, per the form. The filer also disclosed recent sales by Rebecca B. Robertson: 20,000 shares sold on 06/16/2025 for $342,737.54 and 7,445 shares sold on 06/17/2025 for $131,267.25. The filing states the securities to be sold were received as compensation and that the signer represents no undisclosed material adverse information.